Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
-
How Trane Technologies' Shari Werwinski Is Leading a Team That Wins Every Day
-
RedChip Companies Announces Sponsorship of the LD Micro Main Event XIX
-
Independent 3D Geophysical Review Ranks Drill Targets at Colosseum
-
Akanda's 20-Tower Expansion Strengthens Its Legacy Inside Mexico’s $7 Billion Telecom Network (NASDAQ: AKAN)
-
NANO Nuclear Energy Included in Morgan Stanley's National Security Index
-
Aeonian Resources Announces Private Placement
-
New Book Reveals the Hidden Strategy Behind the World's Smartest Brands
-
VEPO Solutions Promotes Tom Moore to President to Drive Continued Growth and Innovation
-
R1 Announces Strategic Partnership with Sierra to Revolutionize AI-Driven Experiences in Healthcare
-
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
-
AEA Private Debt Closes $550 Million Credit Continuation Vehicle, Led by Carlyle AlpInvest
-
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
-
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
-
MMC Elevates Beauty into Standalone Practice
-
Canfornav opens a new office in Hong Kong
-
Delivering on Voter Priorities for Housing Affordability Is Key to Arizona's Economic Future
-
HOLDCO ASSET MANAGEMENT ISSUES PUBLIC PRESENTATION TO THE BOARD OF DIRECTORS OF EASTERN BANKSHARES, INC.
-
Arnatar Therapeutics Announces Upcoming Presentations at AASLD The Liver Meeting® 2025 and ASN Kidney Week 2025
-
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
-
The results of the EMPRESS study show the activity of giredestrant in reducing tumor proliferation in ER+/HER2- breast cancer at early stages without the need for ovarian function suppression
-
CervoMed to Present at the Emerging Growth Conference
-
Lucid Goes Courtside: New Collaboration with Basketball Superstars Brings Performance & Ambition Together Like Never Before
-
VantageScore Adoption Surges: Lenders Flock to Superior Predictive Capabilities Powered by Trended, Alternative Data
-
Maxus Mining Announces Appointment of Robert Eckford as Technical Advisor & Marketing Agreement
-
WiMi Develops Single-Qubit Quantum Neural Network Technology for Multi-Task Design
-
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
-
STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek
-
Judo Bio Presents Data Demonstrating Sustained, Kidney-Selective Gene Silencing Across Species
-
GSI Technology to Announce Fiscal Second Quarter 2026 Results on October 30, 2025
-
The Jackson Laboratory acquires New York Stem Cell Foundation to transform biomedical research and accelerate precision therapies for patients
-
ProtoArc launches Flexer Series ergonomic chairs for extended sitting periods
-
Cure HHT's Registry Research Selected for Oral Presentation at American Society of Hematology 2025 Annual Meeting
-
Early Registration Now Open for 4th Annual 5K at the Runway at Ontario International Airport
-
Lower mortgage rates extend housing momentum into fall
-
Meridian Senior Living Residents to Be Featured in the Vintage Voices 100 Tour
-
Cyber Advice Announces Launch of New Website
-
Seraphic Named a Leader and Fast Mover in the 2025 GigaOm Radar Report for Secure Enterprise Browsing
-
Aqua Metals Closes $13 Million Capital Raise with Prominent Institutional Investor, Company Poised to Accelerate Commercialization Strategy
-
Kandu, Inc. Announces Expansion of Executive Leadership Team and Board of Directors
-
Connect Expands Access to Funding Through Curated Venture List
-
Oracle Enhances Public Safety Suite for Real-Time Data Intelligence
-
Huntington Bank Completes Merger with Veritex, Deepening Commitment to Texas
-
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
-
Heven AeroTech Expands U.S. Operations with New Headquarters in Sterling, Virginia
-
Oportun Completes $441 Million Asset Backed Securitization
-
Valitor Presents Preclinical Data Demonstrating VLTR-559 Achieves Superior Durability and Sustained Anti-VEGF Activity with a Favorable Safety Profile as a Treatment for Wet AMD
-
Switch Raises $659 Million in Fourth Data Center ABS Offering
-
MBX Biosciences to Participate in November Investor Conferences
-
Remsoft Acquires Australian Forestry Tech Firm LOGR, Expanding Global Forest Intelligence Platform
